AVEO Stock Hits New 52-Week Low (AVEO)

NEW YORK ( TheStreet) -- AVEO Pharmaceuticals (Nasdaq: AVEO) hit a new 52-week low Monday as it is currently trading at $12.36, below its previous 52-week low of $12.42 with 134,988 shares traded as of 12:39 p.m. ET. Average volume has been 306,900 shares over the past 30 days.

AVEO has a market cap of $604.4 million and is part of the health care sector and drugs industry. Shares are down 27.2% year to date as of the close of trading on Friday.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of cancer therapeutics. The company has a P/E ratio of 17.3, above the average drugs industry P/E ratio of 10 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates AVEO as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. You can view the full AVEO Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement

When Eyeing Small Biotechs, Partnerships Are Huge

When Eyeing Small Biotechs, Partnerships Are Huge

Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales